vs
华美银行集团（EWBC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
华美银行集团的季度营收约是Royalty Pharma plc的1.2倍（$774.0M vs $622.0M），华美银行集团净利率更高（46.3% vs 34.4%，领先11.8%），华美银行集团同比增速更快（11.8% vs 4.8%），过去两年华美银行集团的营收复合增速更高（18.3% vs 4.6%）
华美银行集团旗下核心子公司为华美银行，是总部位于美国南加州的最大上市银行控股集团。集团资产规模超100亿美元，曾获评标普全球市场财智全美最佳银行，自2023年起连续三年位列《银行董事》杂志同资产规模银行绩效榜单首位。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
EWBC vs RPRX — 直观对比
营收规模更大
EWBC
是对方的1.2倍
$622.0M
营收增速更快
EWBC
高出7.1%
4.8%
净利率更高
EWBC
高出11.8%
34.4%
两年增速更快
EWBC
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $774.0M | $622.0M |
| 净利润 | $358.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | — | 62.4% |
| 净利率 | 46.3% | 34.4% |
| 营收同比 | 11.8% | 4.8% |
| 净利润同比 | 0.4% | 2.9% |
| 每股收益（稀释后） | $2.57 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWBCRPRX
| Q1 26 | $774.0M | — | ||
| Q4 25 | $657.8M | $622.0M | ||
| Q3 25 | $677.5M | $609.3M | ||
| Q2 25 | $617.1M | $578.7M | ||
| Q1 25 | $600.2M | $568.2M | ||
| Q4 24 | $587.6M | $593.6M | ||
| Q3 24 | $572.7M | $564.7M | ||
| Q2 24 | $553.2M | $537.3M |
净利润EWBCRPRX
| Q1 26 | $358.0M | — | ||
| Q4 25 | $356.3M | $214.2M | ||
| Q3 25 | $368.4M | $288.2M | ||
| Q2 25 | $310.3M | $30.2M | ||
| Q1 25 | $290.3M | $238.3M | ||
| Q4 24 | $293.1M | $208.2M | ||
| Q3 24 | $299.2M | $544.0M | ||
| Q2 24 | $288.2M | $102.0M |
营业利润率EWBCRPRX
| Q1 26 | — | — | ||
| Q4 25 | 71.0% | 62.4% | ||
| Q3 25 | 68.6% | 70.1% | ||
| Q2 25 | 65.2% | 36.3% | ||
| Q1 25 | 65.2% | 94.0% | ||
| Q4 24 | 60.6% | 60.9% | ||
| Q3 24 | 68.0% | — | ||
| Q2 24 | 65.9% | 50.2% |
净利率EWBCRPRX
| Q1 26 | 46.3% | — | ||
| Q4 25 | 54.2% | 34.4% | ||
| Q3 25 | 54.4% | 47.3% | ||
| Q2 25 | 50.3% | 5.2% | ||
| Q1 25 | 48.4% | 41.9% | ||
| Q4 24 | 49.9% | 35.1% | ||
| Q3 24 | 52.2% | 96.3% | ||
| Q2 24 | 52.1% | 19.0% |
每股收益（稀释后）EWBCRPRX
| Q1 26 | $2.57 | — | ||
| Q4 25 | $2.55 | $0.49 | ||
| Q3 25 | $2.65 | $0.67 | ||
| Q2 25 | $2.24 | $0.07 | ||
| Q1 25 | $2.08 | $0.55 | ||
| Q4 24 | $2.10 | $0.46 | ||
| Q3 24 | $2.14 | $1.21 | ||
| Q2 24 | $2.06 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $9.0B | $9.7B |
| 总资产 | $82.9B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资EWBCRPRX
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $618.7M | ||
| Q3 25 | $4.7B | $938.9M | ||
| Q2 25 | $4.4B | $631.9M | ||
| Q1 25 | $3.4B | $1.1B | ||
| Q4 24 | $5.3B | $929.0M | ||
| Q3 24 | $4.9B | $950.1M | ||
| Q2 24 | $4.4B | $1.8B |
总债务EWBCRPRX
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $9.0B | ||
| Q3 25 | $35.7M | $8.9B | ||
| Q2 25 | $35.8M | $8.0B | ||
| Q1 25 | $35.9M | $7.6B | ||
| Q4 24 | $36.0M | $7.6B | ||
| Q3 24 | $36.1M | $7.6B | ||
| Q2 24 | $36.1M | $7.6B |
股东权益EWBCRPRX
| Q1 26 | $9.0B | — | ||
| Q4 25 | $8.9B | $9.7B | ||
| Q3 25 | $8.6B | $9.6B | ||
| Q2 25 | $8.2B | $9.5B | ||
| Q1 25 | $7.9B | $9.8B | ||
| Q4 24 | $7.7B | $10.3B | ||
| Q3 24 | $7.7B | $10.3B | ||
| Q2 24 | $7.2B | $9.8B |
总资产EWBCRPRX
| Q1 26 | $82.9B | — | ||
| Q4 25 | $80.4B | $19.6B | ||
| Q3 25 | $79.7B | $19.3B | ||
| Q2 25 | $78.2B | $18.3B | ||
| Q1 25 | $76.2B | $17.6B | ||
| Q4 24 | $76.0B | $18.2B | ||
| Q3 24 | $74.5B | $18.0B | ||
| Q2 24 | $72.5B | $17.7B |
负债/权益比EWBCRPRX
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | 0.92× | ||
| Q3 25 | 0.00× | 0.93× | ||
| Q2 25 | 0.00× | 0.84× | ||
| Q1 25 | 0.00× | 0.78× | ||
| Q4 24 | 0.00× | 0.74× | ||
| Q3 24 | 0.00× | 0.74× | ||
| Q2 24 | 0.01× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流EWBCRPRX
| Q1 26 | — | — | ||
| Q4 25 | $713.4M | $827.1M | ||
| Q3 25 | $231.7M | $702.6M | ||
| Q2 25 | $278.7M | $364.0M | ||
| Q1 25 | $277.9M | $596.1M | ||
| Q4 24 | $500.1M | $742.5M | ||
| Q3 24 | $386.1M | $703.6M | ||
| Q2 24 | $259.2M | $658.2M |
现金转化率EWBCRPRX
| Q1 26 | — | — | ||
| Q4 25 | 2.00× | 3.86× | ||
| Q3 25 | 0.63× | 2.44× | ||
| Q2 25 | 0.90× | 12.06× | ||
| Q1 25 | 0.96× | 2.50× | ||
| Q4 24 | 1.71× | 3.57× | ||
| Q3 24 | 1.29× | 1.29× | ||
| Q2 24 | 0.90× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EWBC
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
